Male breast cancer

Displaying 8 studies

  • Inherited Breast Cancer Study Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN

    The purpose of this study is to improve the interpretation of mutations in breast cancer predisposition genes. This will be accomplished by recruiting members of families found to carry deleterious (mainly protein truncating) mutations and evaluating co-segregation of the mutations with cancer within families.

  • Male Breast Cancer: Understanding The Biology For Improved Patient Care Rochester, MN

    Rationale: Gathering medical information and tumor samples from patients with male breast cancer may help doctors learn more about the disease.

    Purpose retrospective part: to perform a large international retrospective analysis of clinical and biological data of male BC patients treated in the participating centers from 1990 to 2010.

    Purpose prospective part: to create a registry of men with breast cancer for a period of 30 months (starting early 2014).

  • Study Of Endocrine Therapy With Or Without Abemaciclib (LY2835219) Following Surgery In Participants With Breast Cancer Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN

    The purpose of this study is to evaluate the safety and effectiveness of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

  • Study Of Magrolimab Combination Therapy To Treat Unresectable, Locally Advanced Or Metastatic Triple-Negative Breast Cancer Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN

    The primary purpose of the Safety-Run-in Cohort 1 of this study is to evaluate the safety, tolerability, and recommended Phase 2 dose of magrolimab in combination with nab-paclitaxel or paclitaxel. In Phase 2 Cohort 1, the study will compare the efficacy of magrolimab in combination with nab-paclitaxel or paclitaxel versus nab-paclitaxel or paclitaxel alone as determined by
    progression-free survival (PFS) by investigator assessment

    The primary purpose of the Safety-Run-in Cohort 2 of this study is to evaluate the safety, tolerability, and recommended Phase 2 dose of magrolimab in combination with sacituzumab govitecan. In Cohort 2 (Safety Run-in Cohort 2 and Phase 2 Cohort 2) the study will evaluate the efficacy of magrolimab in combination ...

  • A Registry For The Collection And Maintenance Of Biological Specimens For Breast Cancer Research Rochester, MN

    The purpose of this registry is to collect and maintain samples of breast tissue from women and men undergoing surgery for a breast related concern at Mayo Clinic Rochester,  to create a biospecimen resource for the study of benign and cancerous breast conditions.

  • Collection Of Specimens And Clinical Data For Patients With Recurrent Or Metastatic Breast Cancer Or Male Breast Cancer Rochester, MN

    The purpose of this study is to collect blood samples and fresh tissue from biopsies of metastatic lesions from Mayo Clinic patients with metastatic breast cancer. The biospecimens will be used for analysis of genetic alterations in germline and tumor DNA and for tracking of response to therapy using blood-based liquid biopsy approaches. 

  • A Study To Evaluate At Home Administration Of Pertuzumab Combined With Trastuzumab To Treat Patients With HER2-Positive Breast Cancer During COVID-19 Pandemic Jacksonville, FL; Rochester, MN

    The purpose of this study is to assess the safety of PH FDC SC when administered at home by an HHNP. Patients will be assessed for safety by regular evaluation of AEs, vital signs, routine clinical laboratory tests (hematology, blood chemistry), LVEF assessments, and by physical examinations.

  • The Circulating Cell-free Genome Atlas Study Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN

    GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.

.

Mayo Clinic Footer